Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Paquinimod is an immunomodulator.1,2,3,4 In vivo, paquinimod reduces splenic counts of Ly6ChiCD115+ inflammatory monocytes and CD11b+CD11c+ dendritic cells in a mouse model of experimental autoimmune encephalomyelitis (EAE).1 Paquinimod (25 mg/kg per day) reduces hepatic fibrosis and accumulation of inflammatory monocytes and neutrophils in the N-IF mouse model of liver fibrosis.2 It delays disease onset and decreases insulitis in non-obese diabetic (NOD) mice.3 Paquinimod (5 and 25 mg/kg) reduces skin thickness, the number of myofibroblasts, and autoantibody production in the tight skin 1 mouse model of systemic sclerosis.4
WARNING This product is not for human or veterinary use.
1. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-
2. The immunomodulatory quinoline-
3. Paquinimod prevents development of diabetes in the non-
4. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J. Dermatol. Sci. 83(1), 52-59 (2016).